Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — Shareholder Meeting (August 2024)
10 slides from Aarti Pharmalabs's shareholder meeting presentation, Aug 7, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
August 07, 2024 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 54
Slide 2: Annual General Meeting August 2024
Annual General Meeting AUG 2024
Slide 3: Snapshot
SNAPSHOT 200+ Products 500+ Global Clients State-of-the-art 3 R&D facilities 56 Patents Filed 50+ Export Countries Manufacturing 6 Units 41 US DMF 2000+ Employees 3 USFDA Units 22 CEP Global CRISIL 15-20% Market Share 0.14x Net Debt/Equity A+/Positive Credit rating in Xanthine 2 Aarti Pharmalabs Lim
Slide 4: Company Overview
COMPANY OVERVIEW • Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a wholly owned subsidiary of renowned Aarti Industries Limited. Got demerged in October 2022 CONSOLIDATED REVENUE (INR Mn) & into a separately listed entity (effective July 2021) EBITDA MARG
Slide 5: Key Milestones
2022 KEY MILESTONES • Expanded block for CSD in Vapi and API in Tarapur units • Acquired land at Atali for future growth • Demerged the pharmaceutical business of Aarti Industries Limited to Aarti Pharmalabs Limited 2017 12 Completed Cofepris, Mexico 2023 audits at Unit 4 11 2013 • Operationalized t
Slide 6: Key Business Segments
KEY BUSINESS SEGMENTS QUARTERLY REVENUE BREAK-UP Xanthine Derivatives & Allied Products 44.0% 50.2% 49.4% 48.9% API & Intermediates 37.6% 36.9% 43.5% 43.4% CDMO/CMO 18.4% 14.2% 6.3% 7.2% Q1FY24 Q2FY24 Q3FY24 Q4FY24 CDMO/CMO API & Intermediates Xanthine Derivatives 5 Aarti Pharmalabs Limited
Slide 7: Annual Consolidated Income Statement
ANNUAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) FY24 FY23 Y-o-Y Operational Revenue 18,526 19,452 (4.8)% Total Expenses 14,666 16,031 (8.5)% EBITDA 3,860 3,421 12.8% EBITDA Margins (%) 20.84% 17.59% 325 Bps Other Income 49 23 NA Depreciation 732 625 17.1% Finance Cost 172 211 (18.5)% PBT 3
Slide 8: Annual Standalone Income Statement
ANNUAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) FY24 FY23 Y-o-Y Operational Revenue 15,021 15,112 (0.6)% Total Expenses 11,560 12,028 (3.9)% EBITDA 3,461 3,084 12.2% EBITDA Margins (%) 23.04% 20.41% 263 Bps Other Income 110 13 NA Depreciation 660 558 18.3% Finance Cost 166 205 (19.0)% PBT 2,
Slide 9: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS OPERATIONAL INCOME (INR Mn) EBITDA (INR Mn) & EBITDA MARGINS (%) PAT(INR Mn) & PAT MARGINS (%) 19,452 18,526 3,860 3,421 2,169 20.84% 1,935 11.71% 17.59% 9.95% FY23 FY24 FY23 FY24 FY23 FY24 EBITDA Margins (%) PAT Margins (%) NET DEBT TO EQUITY (x) RoCE(%) & RoE(%) 1
Slide 10: Thank You
THANK YOU AARTI PHARMALABS LIMITED